Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AP-144 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Alphageneron
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
AP-144 + Keytruda is a combination immunotherapy regimen being developed by Alphageneron for the treatment of Stage IV non-small cell lung cancer (NSCLC). The regimen combines AP-144, an autologous cell therapy comprising natural killer (NK) cells that have been activated ex vivo to target membrane-bound Heat Shock Protein 70 (Hsp70), with Keytruda (pembrolizumab), a programmed death receptor-1 (PD-1) blocking monoclonal antibody. Hsp70 is frequently overexpressed on the surface of tumor cells, providing a specific target for the cytotoxic NK cells. By combining this targeted cell therapy with pembrolizumab-mediated checkpoint blockade, the treatment aims to overcome tumor-induced immunosuppression and promote a more robust and sustained anti-cancer immune response. The combination is currently being evaluated in Phase 2 clinical trials.
- Other names
- AP-144 + KeytrudaAP-144 + pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on AP-144 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AP-144 + pembrolizumab.